[C:1]([C:4]1[CH:12]=[C:11]([C:13]([CH3:16])([CH3:15])[CH3:14])[CH:10]=[C:9]2[C:5]=1[CH2:6][CH2:7][C:8]2([CH3:18])[CH3:17])(=O)[CH3:2].C(C1C=C2C(CCC2(C)C)=C(C=C)C=1)(C)(C)C.C([N-]C(C)C)(C)C.[Li+].P(Cl)(OCC)(OCC)=O.P([O-])([O-])([O-])=O>>[C:13]([C:11]1[CH:10]=[C:9]2[C:5]([CH2:6][CH2:7][C:8]2([CH3:18])[CH3:17])=[C:4]([C:1]#[CH:2])[CH:12]=1)([CH3:16])([CH3:15])[CH3:14]With reference to Table A, 4-acetyl-6-tert-butyl-1,1-dimethylindane (1) is converted into the intermediate 6-tert-butyl-4-ethenyl-1,1-dimethylindane by treatment with lithium diisopropylamide (LDA) and is then treated with an alkyl chlorophosphate, such as diethyl chlorophosphate. The resulting mixed phosphate intermediate is subsequently again treated with LDA and thus results in the 6-tert-butyl-4-ethynyl-1,1-dimethylindane (2).